The study investigated the effect of caffeine on physical performance in healthy citizens aged over 70 years. The main hypothesis was that 6 mg/kg caffeine would improve cycling endurance at 65% of expected maximal heart rate.

Condition	Intervention	Phase
Healthy elderly citizens	Drug: Caffeine	Phase IV

Further Study Details: 

Expected Total Enrollment:  30

Caffeine ingestion increases the endurance of young people exercising at 60%-85% of their maximal oxygen uptake, and it also seems to improve endurance as measured by repeated sub-maximal isometric contraction and decreases the rate of perceived exertion during exercise. Although caffeine increases endurance in young people, an increase in endurance may be of greater interest in the elderly as the population of older adults with a physically active lifestyle is growing rapidly or for increasing endurance fitness through an exercise or rehabilitation program. Therefore the main hypothesis was that caffeine would improve cycling endurance at 65% of expected maximal heart rate, and the secondary hypotheses were that caffeine would improve postural stability, reaction and movement times, isometric arm flexion endurance, and walking speed, and would reduce the rate of perceived exertion after 5 minutes of cycling in healthy elderly citizens.

Ages Eligible for Study:  70 Years and above,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Healthy elderly individuals aged over 70 years

Exclusion Criteria:

• Dementia or invalidating psychiatric disease
• General debility, angina, or other diseases that would render participation in the test program impossible
• Treatment with beta receptor blocking drugs, calcium-channel blocking drugs, digitalis, or nitroglycerine
• Acute disease and injury
• Diabetes
• Conditions that would contraindicate caffeine ingestion or participation in the test program
• Treatment with medication that interacts with caffeine
• Ingestion of caffeine containing drinks and foods 48 hours before each session

Denmark, Ringkjoebing
      Surgical Research Department, Herning,  Ringkjoebing,  7400,  Denmark

Study chairs or principal investigators

Charlotte Buchard Norager, M.D,  Principal Investigator,  Surgical Research Department, Herning Hospital, DK-7400 Herning   

Study ID Numbers:  2612-1987
Last Updated:  August 1, 2005
Record first received:  July 6, 2005
ClinicalTrials.gov Identifier:  NCT00117520
Health Authority: Denmark: National Board of Health
ClinicalTrials.gov processed this record on 2005-08-02